Department of Social Territorial Medicine, Section of Dermatology, University of Messina, Messina, Italy.
Am J Clin Dermatol. 2010;11 Suppl 1:51-2. doi: 10.2165/1153426-S0-000000000-00000.
Nicolau syndrome (NS), or embolia cutis medicamentosa, is a well-known but rare adverse effect of a still largely unidentified pathogenesis, observed primarily after the intramuscular administration of various drugs. NS is characterized by immediate excruciating pain, early pallor and erythema and oedema at the injection site, followed by cutaneous, subcutaneous and even muscular aseptic necrosis in a livedoid pattern. It is a potentially serious reaction that is little influenced by which drug is injected. A case is reported of NS following a subcutaneous self-injection of etanercept for psoriasis and psoriatic arthritis. This case is remarkable because NS developed after subcutaneous and not after intramuscular drug administration, and because no cases of NS following the injection of tumour necrosis factor alpha inhibitors have been reported in the literature or in the World Health Organization adverse drug reactions database. Although not directly linked to the drug, the occurrence of NS has to be considered in patients receiving biological agents.
尼科劳综合征(Nicolau syndrome,NS),又称药物外溢性脂肪坏死,是一种广为人知但罕见的不良反应,其发病机制目前仍不完全明确,主要发生于多种药物的肌内注射后。NS 的特征为注射部位即刻出现剧烈疼痛,早期苍白、红斑和水肿,随后出现皮肤、皮下组织,甚至肌肉的无菌性坏死,呈类似游走性脉管炎的表现。这是一种潜在的严重不良反应,与注射的药物种类关系不大。本文报告了一例接受依那西普治疗银屑病和银屑病关节炎患者出现 NS 的病例。这例病例较为特殊,因为 NS 是在皮下注射后而不是肌内注射后发生的,且目前文献或世界卫生组织药物不良反应数据库中均无 TNF-α 抑制剂注射后发生 NS 的报道。虽然与药物无直接关系,但在接受生物制剂治疗的患者中仍需考虑 NS 的发生。